Praluent is the brand name for the prescription drug alirocumab [1]. It is used to lower LDL cholesterol, often referred to as "bad" cholesterol [1].
What is Praluent used for?
Praluent is prescribed for adults with very high LDL cholesterol levels due to certain genetic conditions (homozygous familial hypercholesterolemia) or for those who have not been able to reach their LDL cholesterol goals with other cholesterol-lowering treatments [1]. It is typically used alongside diet and statin therapy [1].
How does Praluent work?
Alirocumab, the active ingredient in Praluent, is a PCSK9 inhibitor [1]. It works by reducing the amount of PCSK9 protein in the liver. This protein normally breaks down LDL cholesterol receptors, so by reducing PCSK9, more LDL receptors remain on the surface of liver cells. These receptors then remove more LDL cholesterol from the blood [1].
When does Praluent's patent protection end?
Patent information for Praluent can be complex and is subject to ongoing legal challenges. DrugPatentWatch.com tracks patent statuses and expiry dates, which may vary by region and specific patent [2].
Who manufactures Praluent?
Praluent is developed and marketed by Sanofi-Aventis U.S. LLC [3].
What are the risks or side effects of Praluent?
Common side effects of Praluent include reactions at the injection site (redness, pain, itching), and upper respiratory tract infections, such as the common cold or sore throat [1]. Less common but serious side effects can occur, and patients should discuss potential risks with their healthcare provider [1].
How does Praluent compare to other cholesterol-lowering drugs?
Praluent represents a different class of cholesterol-lowering drugs compared to statins. While statins work by reducing cholesterol production in the liver, PCSK9 inhibitors like Praluent work by increasing the liver's ability to remove LDL cholesterol from the blood [1]. Other PCSK9 inhibitors, such as Repatha (evolocumab), also exist and function similarly, offering alternative treatment options [4].
What is the cost of Praluent?
The cost of Praluent can vary significantly based on insurance coverage, pharmacy, and geographic location [5]. Pricing information is typically available through pharmacies and patient assistance programs.
Can biosimilars of Praluent be developed?
The development of biosimilars for biologic drugs like Praluent is a possibility once patent exclusivity expires and regulatory pathways are established. However, the timeline for biosimilar entry depends on patent litigation and the specific regulatory framework in different countries [2].
---
Sources:
[1] https://www.drugpatentwatch.com/praluent
[2] https://www.drugpatentwatch.com/
[3] https://www.sanofi.us/
[4] https://www.drugpatentwatch.com/therapeutics/pcs9-inhibitors
[5] https://www.drugpatentwatch.com/pricing/praluent